{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:16:57Z","timestamp":1790835417467,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.brainres.2005.12.014","type":"journal-article","created":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T15:23:45Z","timestamp":1137597825000},"page":"209-219","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease"],"prefix":"10.1016","volume":"1073-1074","author":[{"given":"Sara","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Scorticati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Garc\u00eda-Arencibia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2005.12.014_bib1","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1523\/JNEUROSCI.20-09-03401.2000","article-title":"Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor","volume":"20","author":"Beltramo","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2005.12.014_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1037\/0735-7044.103.1.36","article-title":"Taste reactivity analysis of 6-hydroxydopamine-induced aphagia: implications for arousal and anhedonia hypotheses of dopamine function","volume":"103","author":"Berridge","year":"1989","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.brainres.2005.12.014_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0301-0082(99)00067-2","article-title":"Functional changes in the basal ganglia circuitry in Parkinson's disease","volume":"62","author":"Blandini","year":"2000","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.brainres.2005.12.014_bib4","first-page":"S105","article-title":"The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease","volume":"47","author":"Brotchie","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainres.2005.12.014_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1471-4892(02)00011-5","article-title":"CB1 cannabinoid receptor signalling in Parkinson's disease","volume":"3","author":"Brotchie","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.brainres.2005.12.014_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nbd.2005.03.002","article-title":"Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and\/or vanilloid receptors in a rat model of multiple sclerosis","volume":"20","author":"Cabranes","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2005.12.014_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","article-title":"The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson's disease","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.brainres.2005.12.014_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/exnr.2002.7891","article-title":"Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway","volume":"175","author":"Deumens","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainres.2005.12.014_bib9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1096\/fj.14.10.1432","article-title":"Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease","volume":"14","author":"Di Marzo","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.brainres.2005.12.014_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.nbd.2004.03.002","article-title":"Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model","volume":"16","author":"El-Banoua","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2005.12.014_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.nbd.2004.10.015","article-title":"Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism","volume":"18","author":"Fern\u00e1ndez-Espejo","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2005.12.014_bib12","series-title":"Cannabinoids","first-page":"479","article-title":"Cannabinoid control of motor function at the basal ganglia","volume":"vol. 168","author":"Fern\u00e1ndez-Ruiz","year":"2005"},{"key":"10.1016\/j.brainres.2005.12.014_bib13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/mds.10289","article-title":"Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"17","author":"Fox","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2005.12.014_bib14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0892-0362(98)00012-9","article-title":"Perinatal \u03949-tetrahydrocannabinol exposure did not alter dopamine transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic neurons of adult male and female rats","volume":"20","author":"Garc\u00eda-Gil","year":"1998","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.brainres.2005.12.014_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/7268","article-title":"Dopamine activation of endogenous cannabinoid signaling in dorsal striatum","volume":"2","author":"Giuffrida","year":"1999","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainres.2005.12.014_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0024-3205(99)00251-9","article-title":"Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide","volume":"65","author":"Gonz\u00e1lez","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.brainres.2005.12.014_bib17","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2005.12.014_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0006-8993(91)90970-7","article-title":"Neuronal localization of cannabinoid receptors in the basal ganglia of the rat","volume":"547","author":"Herkenham","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2005.12.014_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0006-8993(01)03149-3","article-title":"6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase","volume":"922","author":"Kunikowska","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2005.12.014_bib20","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1046\/j.0953-816x.2001.01812.x","article-title":"Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets","volume":"14","author":"Lastres-Becker","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.brainres.2005.12.014_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainres.2005.12.014_bib22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1046\/j.1471-4159.2003.01759.x","article-title":"Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism","volume":"85","author":"Maccarrone","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainres.2005.12.014_bib23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0306-4522(92)90409-U","article-title":"Distribution of neuronal cannabinoid receptor in the adult brain: a comparative receptor binding radioautography and in situ hybridization histochemistry","volume":"48","author":"Mailleux","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainres.2005.12.014_bib24","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1471-4159.1993.tb09807.x","article-title":"Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study","volume":"61","author":"Mailleux","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainres.2005.12.014_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0014-2999(96)00326-3","article-title":"Activation of the cannabinoid receptor by \u03949-tetrahydrocannabinol reduces GABA uptake in the globus pallidus","volume":"308","author":"Maneuf","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainres.2005.12.014_bib26","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0028-3908(01)00012-0","article-title":"Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum","volume":"40","author":"Meschler","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2005.12.014_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130100728","article-title":"Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates","volume":"156","author":"Meschler","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainres.2005.12.014_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","article-title":"Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson's disease","volume":"27","author":"Mesnage","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.brainres.2005.12.014_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0378-4347(00)81411-5","article-title":"Highly sensitive assay for tyrosine-hydroxylase activity by high-performance liquid chromatography","volume":"163","author":"Nagatsu","year":"1979","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.brainres.2005.12.014_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00726-001-0128-0","article-title":"The role of striatal metabotropic glutamate receptors in Parkinson's disease","volume":"23","author":"Ossowska","year":"2002","journal-title":"Amino Acids."},{"key":"10.1016\/j.brainres.2005.12.014_bib31","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.brainres.2005.12.014_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.brainres.2005.12.014_bib33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ana.20462","article-title":"High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients","volume":"57","author":"Pisani","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainres.2005.12.014_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0166-4328(01)00168-1","article-title":"Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease","volume":"122","author":"Rodriguez Diaz","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.brainres.2005.12.014_bib35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0006-8993(95)00835-E","article-title":"Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function","volume":"694","author":"Romero","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2005.12.014_bib36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0024-3205(97)01117-X","article-title":"The activation of cannabinoid receptors in striatonigral neurons inhibited GABA uptake","volume":"62","author":"Romero","year":"1998","journal-title":"Life Sci."},{"key":"10.1016\/j.brainres.2005.12.014_bib37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0024-3205(99)00618-9","article-title":"Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen","volume":"66","author":"Romero","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.brainres.2005.12.014_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1385-299X(97)00034-2","article-title":"An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism","volume":"2","author":"Rozas","year":"1997","journal-title":"Brain Res. Protoc."},{"key":"10.1016\/j.brainres.2005.12.014_bib39","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/00001756-199412000-00022","article-title":"Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study","volume":"5","author":"Rubino","year":"1994","journal-title":"NeuroReport"},{"key":"10.1016\/j.brainres.2005.12.014_bib40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1006\/exnr.2001.7649","article-title":"Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease","volume":"169","author":"Silverdale","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainres.2005.12.014_bib41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0378-4347(93)E0391-3","article-title":"Measurement of GABA in rat brain microdialysates using o-phtaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection","volume":"652","author":"Smith","year":"1994","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.brainres.2005.12.014_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3940(99)00762-4","article-title":"Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats","volume":"276","author":"Zeng","year":"1999","journal-title":"Neurosci. Lett."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899305017269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899305017269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T15:30:57Z","timestamp":1626967857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899305017269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":42,"alternative-id":["S0006899305017269"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2005.12.014","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}